Kallikrein Inhibitor cas: 97145-43-2

CAS NO: 97145-43-2
Kallikrein Inhibitor
Chemical Name: KKI 5
Molecular Formula: C35H55N11O9
Formula Weight: 773.88
CAS No.: 97145-43-2
Description Review
Description

Kallikrein inhibitor is a synthetic chemical compound that inhibits the activity of kallikrein, an enzyme involved in blood clotting and inflammation. It is used in the treatment of various conditions such as angioedema and hereditary angioedema. In this article, we will discuss the chemical and physical properties of kallikrein inhibitor, its health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.

Chemical Name Ecallantide

Molecular Formula C305H442N88O84S7

Formula Weight 7116.99 g/mol

CAS No 97145-43-2

Top Ten Keywords from Google

  1. Kallikrein inhibitor
  2. Ecallantide
  3. Angioedema
  4. Hereditary angioedema
  5. Blood clotting
  6. Inflammation
  7. Bradykinin
  8. Peptide therapy
  9. HAE treatment
  10. Drug interactions

Synonyms

  • DX-88
  • Kalbitor
  • Kallikrein-blocking peptide

Health Benefits of this Product Kallikrein inhibitor has a number of potential health benefits due to its ability to inhibit the activity of kallikrein. Some of the most important health benefits of this peptide include:

  1. Angioedema treatment: Kallikrein inhibitor is primarily used for the treatment of angioedema, a condition characterized by swelling under the skin and mucosa. It is particularly effective in treating hereditary angioedema.

  2. Blood clot prevention: Kallikrein inhibitors may help prevent blood clots from forming by inhibiting the activity of kallikrein, which is involved in the coagulation process.

Potential Effects The potential effects of kallikrein inhibitor are numerous and varied. Some of the most notable effects of this peptide include:

  1. Inhibition of kallikrein: As the name suggests, kallikrein inhibitor prevents kallikrein from functioning properly. This can help prevent the formation of blood clots and reduce inflammation.

  2. Bradykinin reduction: Kallikrein is involved in the production of bradykinin, a peptide that causes blood vessels to dilate and contributes to inflammation. By inhibiting kallikrein, kallikrein inhibitor can reduce the amount of bradykinin in the body.

Product Mechanism Kallikrein inhibitor works by binding to and inhibiting the activity of kallikrein, an enzyme involved in blood clotting and inflammation. Kallikrein produces bradykinin, a peptide that contributes to inflammation and swelling. By inhibiting kallikrein, kallikrein inhibitor reduces the production of bradykinin, resulting in reduced inflammation and swelling.

Safety Kallikrein inhibitor is generally considered to be safe when used as directed. However, like all medications, it can cause side effects in some people. It is important to discuss the risks and benefits of using kallikrein inhibitor with your healthcare provider before starting treatment.

Side Effects Some of the most common side effects of kallikrein inhibitor include headache, nausea, and diarrhea. Other possible side effects include allergic reactions and injection site reactions. If you experience any of these side effects, it is important to contact your healthcare provider immediately.

Dosing Information The dose of kallikrein inhibitor will vary depending on the individual and the condition being treated. It is important to follow the dosing instructions provided by your healthcare provider.

Conclusion In conclusion, kallikrein inhibitor is a powerful drug that inhibits the activity of kallikrein, an enzyme involved in blood clotting and inflammation. Its ability to reduce the production of bradykinin makes it a valuable tool in the treatment of conditions such as angioedema and hereditary angioedema. However, like all medications, it can cause side effects in some people, and it is important to discuss the risks and benefits of using it with your healthcare provider before starting treatment. Despite some possible side effects, kallikrein inhibitor is a promising new tool in the field of peptide therapy that may help to improve outcomes for patients with a variety of conditions.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code